Candel Therapeutics, Inc. CADL Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s investing cash flow?
- Candel Therapeutics, Inc. (CADL) reported investing cash flow of -$675K in Q1 2026.
- How has Candel Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Candel Therapeutics, Inc.'s investing cash flow decreased by 22400.0% year-over-year, from -$3K to -$675K.
- What is the long-term trend for Candel Therapeutics, Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s investing cash flow has grown at a -25.7% compound annual growth rate (CAGR), from -$1.84M to -$560K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.